SL-701: Revision history

From Glioblastoma Treatments
Jump to navigationJump to search

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

12 November 2024

31 March 2024

  • curprev 13:3213:32, 31 March 2024‎ Lazy talk contribs‎ 2,406 bytes +45‎ No edit summary
  • curprev 13:1413:14, 31 March 2024‎ Lazy talk contribs‎ 2,361 bytes +2,361‎ Created page with "{{TreatmentInfo |drug_name=SL-701 (Immunotherapy Vaccine) |FDA_approval=In clinical trials; not yet FDA-approved |used_for=Relapsed or refractory Glioblastoma Multiforme (GBM) |clinical_trial_phase=Phase II |common_side_effects=Fatigue, injection site reaction, erythema, and pain were the most common treatment-related adverse events. No grade 4/5 adverse events reported, indicating a manageable safety profile. |OS_without=Historical controls suggest a median overall surv..."
Retrieved from "http://glioblastomatreatments.wiki:80/index.php?title=SL-701"